Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Lyne

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Clinical Therapeutics|November 24, 2007
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 yearsJames C Kisicki, Kimberly Fiske, Andrew Lyne
Nature|August 31, 2012
Bernard Lovell (1913-2012)Francis Graham Smith, Rodney Davies, Andrew Lyne
BMJ Case Reports|June 15, 2021
COVID-19-induced postural orthostatic tachycardia syndrome treated with ivabradineJenna Stephanie O'Sullivan, Andrew Lyne, Carl J Vaughan
Science (New York, N.Y.)|June 26, 2010
Switched magnetospheric regulation of pulsar spin-downAndrew Lyne, George Hobbs, Michael Kramer, et al.
Clinical Therapeutics|July 10, 2007
A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adultsDennis Swearingen, Michael Pennick, Amir Shojaei, et al.
Journal of Child and Adolescent Psychopharmacology|June 13, 2009
Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorderFloyd R Sallee, Andrew Lyne, Timothy Wigal, et al.
Journal of Child and Adolescent Psychopharmacology|October 7, 2014
Efficacy of guanfacine extended release assessed during the morning, afternoon, and evening using a modified Conners' Parent Rating Scale-revised: Short FormJoel Young, Thomas Rugino, Ryan Dammerman, et al.
Pharmacotherapy|August 29, 2007
Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorderSamuel W Boellner, Michael Pennick, Kimberly Fiske, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|December 25, 2008
Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trialFloyd R Sallee, James McGough, Tim Wigal, et al.
Leukemia Research|March 10, 2005
Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disordersSteven M Fruchtman, Robert M Petitt, Harriet S Gilbert, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Clinical Therapeutics|November 24, 2007
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 yearsJames C Kisicki, Kimberly Fiske, Andrew Lyne
Nature|August 31, 2012
Bernard Lovell (1913-2012)Francis Graham Smith, Rodney Davies, Andrew Lyne
BMJ Case Reports|June 15, 2021
COVID-19-induced postural orthostatic tachycardia syndrome treated with ivabradineJenna Stephanie O'Sullivan, Andrew Lyne, Carl J Vaughan
Science (New York, N.Y.)|June 26, 2010
Switched magnetospheric regulation of pulsar spin-downAndrew Lyne, George Hobbs, Michael Kramer, et al.
Clinical Therapeutics|July 10, 2007
A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adultsDennis Swearingen, Michael Pennick, Amir Shojaei, et al.
Journal of Child and Adolescent Psychopharmacology|June 13, 2009
Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorderFloyd R Sallee, Andrew Lyne, Timothy Wigal, et al.
Journal of Child and Adolescent Psychopharmacology|October 7, 2014
Efficacy of guanfacine extended release assessed during the morning, afternoon, and evening using a modified Conners' Parent Rating Scale-revised: Short FormJoel Young, Thomas Rugino, Ryan Dammerman, et al.
Pharmacotherapy|August 29, 2007
Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorderSamuel W Boellner, Michael Pennick, Kimberly Fiske, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|December 25, 2008
Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trialFloyd R Sallee, James McGough, Tim Wigal, et al.
Leukemia Research|March 10, 2005
Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disordersSteven M Fruchtman, Robert M Petitt, Harriet S Gilbert, et al.
Pageof 3